𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia

✍ Scribed by Aldoss, Ibrahin; Mark, Lisa; Vrona, Janice; Ramezani, Laleh; Weitz, Ilene; Mohrbacher, Ann M.; Douer, Dan

Book ID
125344211
Publisher
Springer
Year
2014
Tongue
English
Weight
182 KB
Volume
93
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Arsenic trioxide and low-dose cytarabine
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
✍ Gail J. Roboz; Ellen K. Ritchie; Tania Curcio; Juliette Provenzano; Rebecca Carl πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 135 KB

## Abstract ## BACKGROUND. Acute myeloid leukemia (AML) carries a dismal prognosis in older patients. In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low‐dose cytarabine in untreated patients aged β‰₯60 years with AML. ## METHODS. In a phase 1/2 desig

An efficient therapeutic approach to pat
An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid
✍ Guanjun Wang; Wei Li; Jiuwei Cui; Sujun Gao; Cheng Yao; Zhenyu Jiang; Yanqiu Son πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 79 KB πŸ‘ 1 views

## Abstract The use of arsenic trioxide (As~2~O~3~, ATO) combined with all‐trans retinoic acid (ATRA) has recently been reported to induce remission in patients with acute promyelocytic leukemia (APL). However, its efficiency remains inconclusive mainly due to the small number of the available case